Price$72.74+0.35 (+0.48%)
01:30 PM07:45 PM
News · 26 weeks72+233%
2025-12-072026-05-31
Mix5090d
- Insider30(60%)
- Other8(16%)
- SEC Filings7(14%)
- Analyst2(4%)
- Earnings2(4%)
- Leadership1(2%)
Latest news
25 items- PRDexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User ExperienceCompany establishes permanent council to drive ongoing innovation guided by community feedback Report outlines targeted commitments Dexcom is making to address sentiments shared by council members Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights to strengthen its techno
- INSIDERDirector Altman Steven R was granted 5,565 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Augustinos Nicholas was granted 5,575 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Foletta Mark G was granted 6,331 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Collins Richard Alexander was granted 5,605 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Gala Renee D was granted 5,605 shares, increasing direct ownership by 81% to 12,486 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- SECDexCom Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - DEXCOM INC (0001093557) (Filer)
- SECSEC Form SD filed by DexCom Inc.SD - DEXCOM INC (0001093557) (Filer)
- INSIDERPresident, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.34% to 420,359 units (SEC Form 4) (withholding tax)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 108,053 units (SEC Form 4) (withholding obligation)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.95% to 151,841 units (SEC Form 4) (tax liability)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 130,059 units (SEC Form 4) (tax withholding)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP, Chief Commercial Officer Coleman Jon covered exercise/tax liability with 7,362 shares, decreasing direct ownership by 7% to 105,273 units (SEC Form 4) to satisfy withholding tax4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERExecutive Chair Sayer Kevin R sold $1,926,648 worth of shares (26,759 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 382,482 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted UsersThrough ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were stolen by a third party before destruction and sold into the market. Dexcom is working closely with the FDA and other authorities to ensure patient safety and to investigate the crime. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine
- SECSEC Form 144 filed by DexCom Inc.144 - DEXCOM INC (0001093557) (Subject)
- INSIDEREVP, Chief Legal Officer Brown Michael Jon sold $101,847 worth of shares (1,700 units at $59.91) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 109,504 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRRedefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in GermanyDexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists1. The new system will be available shortly. Dexcom Flex provides real-time glucose data, personalised behavioural insights, and simplified tracking tools to support informed decision-making. DexCom, Inc. (NASDAQ:DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. This press release features multimedia. View the full release here: https://www.
- INSIDERDirector Heller Bridgette P sold $60,730 worth of shares (1,012 units at $60.01) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 25,007 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom Announces Governance Enhancements Ahead of 2026 Investor DayWill Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date Reconstituted Operations and Innovation Committee Will Expand Mandate to Oversee Operations, Quality and Technical Roadmap Initiatives Follow Constructive Engagement with Elliott Management DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. "We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosen
DXCM FAQ
7 questionsWhat does DexCom Inc. do?
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop...Where does DXCM stock trade?
DexCom Inc. (DXCM) is listed on NASDAQ.What sector and industry is DXCM in?
DexCom Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did DexCom Inc. go public?
DexCom Inc. (DXCM) completed its IPO in 2005.What are analysts saying about DXCM?
DexCom Inc. has had 8 recent analyst actions on file. The most recent action was from The Benchmark Company: Buy on 2026-05-12.What companies are similar to DXCM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare DXCM side-by-side with any of them on Quantisnow.How can I track DXCM on Quantisnow?
Quantisnow aggregates DexCom Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DXCM to receive live email and push alerts on every new disclosure.